Impact of Chronic Antiplatelet Therapy on Infarct Size and Bleeding in Patients With Acute Myocardial Infarction

La terapia antiaggregante (singola o doppia) nei pazienti con IMA ha effetti favorevoli o si associa a un aumento del rischio? ( J Cardiovasc Pharmacol Ther 2018 Jan 1)

23 April Apr 2018 7 years ago
  • Campodonico J, Cosentino N, Milazzo V, Rubino M, De Metrio M, Marana I, Moltrasio M, Grazi M, Lauri G, Bonomi A, Veglia F, Chiorino E, Assanelli E, Bartorelli AL, Marenzi G
QR Code

Patients hospitalized with acute myocardial infarction (AMI) are often on prior single antiplatelet therapy (SAPT) or a dual antiplatelet therapy (DAPT). Whether chronic SAPT or DAPT is beneficial or associated with an increased risk in AMI is still controversial.

In patients with AMI, chronic antiplatelet therapy is associated with higher baseline ischemic and bleeding risks. Despite this and unexpectedly, they have a smaller infarct size and similar adjusted bleeding risk.

Reference
1. Campodonico J, Cosentino N, Milazzo V, Rubino M, De Metrio M, Marana I, Moltrasio M, Grazi M, Lauri G, Bonomi A, Veglia F, Chiorino E, Assanelli E, Bartorelli AL, Marenzi G. Impact of Chronic Antiplatelet Therapy on Infarct Size and Bleeding in Patients With Acute Myocardial Infarction. J Cardiovasc Pharmacol Ther 2018 Jan 1:1074248418769636. doi: 10.1177/1074248418769636. [Epub ahead of print] Go to PubMed